



This document is an English translation of a statement written originally in Japanese. The Japanese original should be considered as the primary version.

Consolidated Financial Results for Six Months Ended November 30, 2024 (Japanese GAAP)

January 14, 2025

Name of Listed Company: CREATE SD HOLDINGS CO., LTD.

Listing: Tokyo Stock Exchange

Securities code: 3148

URL: <https://www.createsdhd.co.jp/English/tabid/129/Default.aspx>

Representative: Taizo Hirose, Representative Director and President

Contact: Tetsuya Yamazaki, Executive Officer and General Manager, Finance and Accounting Dept.

Tel: +81-45-914-8241

Scheduled filing date of Securities Report:
January 14, 2025

Scheduled date of start of dividend payment:
February 4, 2025

Supplementary materials for the financial results: Yes

Financial results briefing sessions: Yes (For institutional investors and securities analysts)

(Figures are rounded down to the nearest million yen)

1. Consolidated Second Quarter (First Half) Results for Fiscal Year Ending May 31, 2025

(June 1, 2024 to November 30, 2024)

(1) Consolidated Operating Results

(Figures in percentages denote the year-on-year change)

| | Net sales | | Operating profit | | Ordinary profit | | Profit attributable to owners of parent | |
|------------------------------------|-----------------|------|------------------|-----|-----------------|-----|---|-----|
| | Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % |
| Six months ended November 30, 2024 | 224,806 | 8.4 | 10,462 | 6.2 | 10,807 | 6.0 | 7,022 | 2.1 |
| Six months ended November 30, 2023 | 207,451 | 10.7 | 9,852 | 6.7 | 10,191 | 7.8 | 6,875 | 7.2 |

(Note) Comprehensive income: Six months ended November 30, 2024: ¥6,982 million (1.5%)
Six months ended November 30, 2023: ¥6,876 million (6.9%)

| | Earnings per share | Diluted earnings per share |
|------------------------------------|--------------------|----------------------------|
| | Yen | Yen |
| Six months ended November 30, 2024 | 108.72 | — |
| Six months ended November 30, 2023 | 108.76 | 102.90 |

(2) Consolidated Financial Position

| | Total assets | Total net assets | Equity ratio |
|-------------------------|-----------------|------------------|--------------|
| | Millions of yen | Millions of yen | % |
| As of November 30, 2024 | 224,946 | 136,031 | 60.5 |
| As of May 31, 2024 | 216,481 | 130,243 | 60.2 |

(Reference) Net assets: As of November 30, 2024: ¥136,031 million
As of May 31, 2024: ¥130,224 million

2. Dividend Payments

| | Dividends per share | | | | |
|--|---------------------|----------------|---------------|----------|--------|
| | First quarter | Second quarter | Third quarter | Year-end | Annual |
| | Yen | Yen | Yen | Yen | Yen |
| Fiscal year ended May 31, 2024 | — | 27.00 | — | 37.00 | 64.00 |
| Fiscal year ending May 31, 2025 | — | 34.00 | | | |
| Fiscal year ending May 31, 2025 (forecast) | | | — | 34.00 | 68.00 |

(Note) Revisions to most recently announced dividend forecast: None

3. Consolidated Financial Forecast (From June 1, 2024 to May 31, 2025)

(Figures in percentages denote the year-on-year change)

| | Net sales | | Operating profit | | Ordinary profit | | Profit attributable to owners of parent | | Earnings per share |
|-----------|-----------------|-----|------------------|-----|-----------------|-----|---|-----|--------------------|
| | Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % | Yen |
| Full-year | 457,600 | 8.4 | 22,000 | 8.8 | 22,400 | 7.3 | 14,400 | 5.2 | 222.90 |

(Note) Revisions to most recently announced financial results forecast: None

Notes

(1) Significant changes in the scope of consolidation in the six months ended November 30, 2024: None
 Newly consolidated: — companies (company name(s)); Deconsolidated: — companies (company name(s))

(2) Application of accounting treatments specific to preparation of consolidated financial statements: Yes

(3) Changes in accounting policies, changes of accounting estimates and restatement

(i) Changes in accounting policies due to amendments to accounting standards: Yes

(ii) Other changes in accounting policies: None

(iii) Changes in accounting estimates: None

(iv) Restatements: None

(4) Issued shares (common shares)

(i) Issued shares (including treasury shares) at period-end:

| | | | |
|------------------------------------|-------------------|------------------------------------|-------------------|
| Six months ended November 30, 2024 | 66,819,342 shares | Fiscal year ended May 31, 2024 | 66,819,342 shares |
| Six months ended November 30, 2024 | 2,217,058 shares | Fiscal year ended May 31, 2024 | 2,576,458 shares |
| Six months ended November 30, 2024 | 64,589,095 shares | Six months ended November 30, 2023 | 63,218,485 shares |

(ii) Treasury shares at period-end:

(iii) Average issued shares during period:

The second quarter (first half) financial statements are not subject to review by a certified public accountant or audit firm.

Cautionary statement regarding business results forecasts and special notes

(Notes concerning forward-looking statements, etc.)

The financial forecasts and other forward-looking statements contained herein are based on currently available information and certain assumptions considered by the Company to be reasonable. Actual financial results may differ materially due to various factors. Refer to “(3) Overview of Consolidated Financial Results Forecast and Future Expectations” on page 3 of the supplementary material for the underlying assumptions and proper use of the forecasts.

Contents

| | |
|--|----|
| 1. Qualitative Information Related to Consolidated Financial Results..... | 2 |
| (1) Overview of Operating Results | 2 |
| (2) Overview of Financial Position | 3 |
| (3) Overview of Consolidated Financial Results Forecast and Future Expectations | 3 |
| 2. Consolidated Financial Statements and Notes | 4 |
| (1) Consolidated Balance Sheet | 4 |
| (2) Consolidated Statements of Income and Comprehensive Income | 6 |
| Consolidated Statement of Income..... | 6 |
| First six months of the fiscal year ending May 31, 2025 | 6 |
| Consolidated Statement of Comprehensive Income..... | 7 |
| First six months of the fiscal year ending May 31, 2025 | 7 |
| (3) Consolidated Statements of Cash Flows..... | 8 |
| (4) Notes to Consolidated Financial Statements | 9 |
| Going concern assumption | 9 |
| Notes in case of significant changes in shareholders' equity..... | 9 |
| Application of specific accounting treatment in the preparation of consolidated financial statements | 9 |
| Changes to accounting policies | 9 |
| Changes in accounting estimates..... | 9 |
| 3. Supplemental Information..... | 10 |
| (1) Production, Orders Received, and Sales..... | 10 |

1. Qualitative Information Related to Consolidated Financial Results

(1) Overview of Operating Results

During the first half of the fiscal year ending May 31, 2025 (June 1, 2024 to November 30, 2024), the Japanese economy showed a gradual recovery trend, supported by improvements in employment and income conditions, as well as an increase in the number of foreign visitors to Japan, signaling progress in the normalization of economic and social activities. However, uncertainties about the future persist due to concerns over a potential slowdown in personal consumption caused by ongoing price increases.

In the drug store industry, the environment surrounding the Company has become increasingly challenging due to the intensified competition from the opening of stores by competitors across different sectors and business models, heightened price competition, and industry consolidation among major players.

Under these circumstances, the Group is promoting comprehensive health care support for regional contribution in the domains of daily life, prevention, medical care, and nursing care as we continue to strengthen our dominant position in existing areas, mainly in in-store prescription drug stores, to achieve the Medium-term Management Plan.

Drug Stores

The drug store business faced a further strengthening of the tendency among households to seek money savings and consume selectively. In response, we continued to promote our everyday low prices (EDLP) strategy offering affordable prices at all times, thus acting as a lifeline to support the health and lifestyles of local customers and patients. We also continued our efforts to realize quick, one-stop shopping by promoting in-store prescription drug stores and improving convenience and expertise in small trade areas by expanding the lineup of fresh foods and other food products.

During the first six-month period ended November 30, 2024, the merchandise sales division continued to see steady growth in both net sales and customer numbers at existing stores driven by the sustained promotion of our EDLP strategy. In the prescriptions division, efforts focused on strengthening collaboration with nearby medical institutions and enhancing the calculation of various reimbursement additions. Additionally, the division worked on establishing a system to handle electronic prescriptions, resulting in steady progress in the number of prescriptions handled and the average prescription unit price. On the cost management front, we actively pursued measures to control labor hours on-site, install solar panels on store rooftops, and operationalize a new logistics center, with an emphasis not only on cost reduction but also on promoting environmentally responsible management.

During the period, we opened 23 new drug stores. On the other hand, we closed two stores, one due to the expiration of contracts, and one from the standpoint of improving management efficiency. In terms of prescription drug stores, we opened 15 in-store prescription drug stores.

Nursing Care

Regarding the nursing care business, amid an aging population, we operate two paid assisted living facilities characterized by delicious meals for elderly people who want to live safely and securely under the care of nursing staff, as well as 37 half-day rehabilitative adult care centers for those who want to continue living at home. For our paid assisted living facilities and adult day care services we have put every effort into customer service, which is one of the distinctive characteristics of our Group, to increase user satisfaction and improve occupancy rates.

Owing to the efforts above, the number of Group stores as of the end of the first half on November 30, 2024, was as follows: 773 drug stores, two supermarkets, and four combination drug store/fresh produce stores. The total number of prescription drug stores was 433, consisting of 37 dedicated prescription drug stores and 396 in-store prescription drug stores. The Group also has two paid assisted living facilities and 37 half-day adult care centers in the nursing care business.

As a result of the above, the financial results for the first six months of the fiscal year ending May 31, 2025 were as follows: Net sales came in at 224,806 million yen (up 8.4% year on year), operating profit was 10,462 million yen (up 6.2%), ordinary profit was 10,807 million yen (up 6.0%), and profit attributable to owners of parent was 7,022 million yen (up 2.1%).

(2) Overview of Financial Position

Total assets as of November 30, 2024 were 224,946 million yen, up 8,465 million yen from the end of the previous fiscal year. The main factors include increases of 2,248 million yen in cash and deposits, 675 million yen in accounts receivable - trade, 1,888 million yen in merchandise, and 5,097 million yen in non-current assets.

Total liabilities as of November 30, 2024 were 88,915 million yen, up 2,676 million yen from the end of the previous fiscal year. The main factors include increases of 635 million yen in accounts payable - trade, 477 million yen in income taxes payable, 472 million yen of accrued expenses included in "Other" under current liabilities, and 419 million yen in provision for losses on cancellation.

Net assets as of November 30, 2024 were 136,031 million yen, up 5,788 million yen from the end of the previous fiscal year. The main factors were a 2,376 million yen decrease due to dividends paid, an increase of 763 million yen in capital surplus due to exercise of share options, a decrease of 438 million yen in treasury shares, and the recording of 7,022 million yen in first half profit attributable to owners of parent.

Cash Flows

Cash and cash equivalents at the end of the first half of the fiscal year under review totaled 40,061 million yen, up 2,248 million yen from the end of the previous fiscal year.

Cash flows for the first half of the fiscal year were as follows:

Cash flows from operating activities

Net cash provided by operating activities amounted to 11,411 million yen, up 1,568 million yen year on year. The main components are as follows: profit before income taxes of 10,354 million yen, depreciation of 2,659 million yen, income taxes refund of 863 million yen, an increase in inventories of 1,899 million yen, an increase in trade payable of 635 million yen, and income taxes paid of 3,041 million yen.

Cash flows from investing activities

Net cash used in investing activities amounted to 7,969 million yen, down 3,677 million yen year on year. This was mainly due to 4,614 million yen of purchase of property, plant and equipment associated with the store openings, and 3,235 million yen for store openings in progress.

Cash flows from financing activities

Net cash used in financing activities amounted to 1,193 million yen, down 490 million yen year on year. This is the result of dividends paid of 2,376 million yen and proceeds from disposal of treasury shares of 1,198 million yen.

(3) Overview of Consolidated Financial Results Forecast and Future Expectations

At this time, no changes have been made to the forecast for the fiscal year ending May 31, 2025 announced on July 8, 2024.

2. Consolidated Financial Statements and Notes

(1) Consolidated Balance Sheet

(Millions of yen)

| | FY2023 (As of May 31, 2024) | 2Q of FY2024 (As of November 30, 2024) |
|--|--------------------------------|---|
| Assets | | |
| Current assets | | |
| Cash and deposits | 38,212 | 40,461 |
| Accounts receivable - trade | 15,431 | 16,106 |
| Merchandise | 42,015 | 43,904 |
| Other | 11,531 | 10,086 |
| Total current assets | 107,191 | 110,558 |
| Non-current assets | | |
| Property, plant and equipment | | |
| Buildings and structures, net | 36,493 | 38,570 |
| Land | 27,274 | 28,904 |
| Other, net | 8,412 | 8,702 |
| Total property, plant and equipment | 72,180 | 76,177 |
| Intangible fixed assets | | |
| Goodwill | 372 | 330 |
| Other | 770 | 691 |
| Total intangible assets | 1,142 | 1,021 |
| Investments and other assets | | |
| Long-term loans receivable | 10,024 | 10,705 |
| Leasehold and guarantee deposits | 11,939 | 12,156 |
| Other | 14,063 | 14,389 |
| Allowance for doubtful accounts | (60) | (61) |
| Total investments and other assets | 35,967 | 37,189 |
| Total non-current assets | 109,290 | 114,388 |
| Total assets | 216,481 | 224,946 |
| Liabilities | | |
| Current liabilities | | |
| Accounts payable - trade | 56,357 | 56,992 |
| Accrued income taxes | 3,444 | 3,922 |
| Accrued bonuses | 387 | 491 |
| Provision for bonuses for directors (and other officers) | 157 | 75 |
| Provision for point card certificates | 160 | 180 |
| Asset retirement obligations | 6 | 13 |
| Provision for loss on store closings | 36 | — |
| Other | 16,974 | 17,814 |
| Total current liabilities | 77,524 | 79,490 |
| Non-current liabilities | | |
| Net defined benefit liability | 3,234 | 3,433 |
| Asset retirement obligations | 3,925 | 4,036 |
| Provision for loss on subleasing | 24 | 20 |
| Provision for losses on cancellation | — | 419 |
| Other | 1,529 | 1,514 |
| Total non-current liabilities | 8,714 | 9,424 |
| Total liabilities | 86,238 | 88,915 |

(Millions of yen)

| | FY2023 (As of May 31, 2024) | 2Q of FY2024 (As of November 30, 2024) |
|---|--------------------------------|---|
| Net assets | | |
| Equity capital | | |
| Share capital | 1,000 | 1,000 |
| Capital surplus | 2,945 | 3,709 |
| Retained earnings | 129,019 | 133,664 |
| Treasury shares | (3,144) | (2,705) |
| Total shareholders' equity | 129,821 | 135,668 |
| Accumulated other comprehensive income | | |
| Valuation difference on available-for-sale securities | 39 | 35 |
| Remeasurements of defined benefit plans | 363 | 327 |
| Total accumulated other comprehensive income | 403 | 363 |
| Share options | 18 | — |
| Total net assets | 130,243 | 136,031 |
| Liabilities and net assets | 216,481 | 224,946 |

(2) Consolidated Statements of Income and Comprehensive Income

Consolidated Statement of Income

(Millions of yen)

| | 1H of FY2023 (From June 1, 2023 to November 30, 2023) | 1H of FY2024 (From June 1, 2024 to November 30, 2024) |
|---|---|---|
| Net sales | 207,451 | 224,806 |
| Cost of sales | 153,485 | 166,557 |
| Gross profit | 53,965 | 58,248 |
| Selling, general and administrative expenses | | |
| Provision for point card certificates | 160 | 180 |
| Salaries and allowances | 17,893 | 19,167 |
| Provision for bonuses | 309 | 491 |
| Provision for directors' bonuses | 74 | 71 |
| Retirement benefit expenses | 384 | 346 |
| Depreciation and amortization | 2,198 | 2,586 |
| Land/office rent | 8,567 | 9,033 |
| Other | 14,525 | 15,908 |
| Total selling, general and administrative expenses | 44,113 | 47,786 |
| Operating profit | 9,852 | 10,462 |
| Non-operating profit | | |
| Interest income | 42 | 52 |
| Dividend income | 0 | 0 |
| Rent income | 175 | 186 |
| Subsidy income | 117 | — |
| Other | 103 | 190 |
| Total non-operating income | 439 | 429 |
| Non-operating expenses | | |
| Compensation expenses | 4 | — |
| Rental expenses | 81 | 81 |
| Other | 14 | 3 |
| Total non-operating expenses | 100 | 84 |
| Ordinary profit | 10,191 | 10,807 |
| Extraordinary profit | | |
| Gain on sale of investment securities | — | 1 |
| Subsidy income | — | 63 |
| Other | — | 0 |
| Total extraordinary income | — | 65 |
| Extraordinary losses | | |
| Loss on sale of non-current assets | 26 | — |
| Loss on retirement of non-current assets | 1 | 15 |
| Loss on tax purpose reduction entry of non-current assets | — | 63 |
| Provision for losses on cancellation losses | — | 419 |
| Other | — | 18 |
| Total extraordinary losses | 28 | 517 |
| Profit before income taxes | 10,163 | 10,354 |
| Income taxes | 3,287 | 3,332 |
| Profit | 6,875 | 7,022 |
| Profit attributable to non-controlling interests | — | — |
| Profit attributable to owners of parent | 6,875 | 7,022 |

Consolidated Statement of Comprehensive Income

(Millions of yen)

| | 1H of FY2023 (From June 1, 2023 to November 30, 2023) | 1H of FY2024 (From June 1, 2024 to November 30, 2024) |
|---|---|---|
| Profit | 6,875 | 7,022 |
| Other comprehensive income | | |
| Valuation difference on available-for-sale securities | 4 | (3) |
| Remeasurements of defined benefit plans, net of tax | (4) | (36) |
| Total other comprehensive income | 0 | (40) |
| Comprehensive income | 6,876 | 6,982 |
| Comprehensive income attributable to: | | |
| Owners of parent | 6,876 | 6,982 |
| Non-controlling interests | — | — |

(3) Consolidated Statements of Cash Flows

(Millions of yen)

| | 1H of FY2023 (From June 1, 2023 to November 30, 2023) | 1H of FY2024 (From June 1, 2024 to November 30, 2024) |
|---|---|---|
| Cash flows from operating activities | | |
| Profit before income taxes | 10,163 | 10,354 |
| Depreciation and amortization | 2,272 | 2,659 |
| Increase (decrease) in allowance for doubtful accounts | (0) | 1 |
| Increase (decrease) in provision for bonuses | (36) | 103 |
| Increase (decrease) in provision for bonuses for directors (and other officers) | (66) | (82) |
| Increase (decrease) in provision for point card certificates | (10) | 20 |
| Increase (decrease) in provision for loss on subleasing | (3) | (3) |
| Increase (decrease) in provision for losses on cancellation | — | 419 |
| Increase (decrease) in retirement benefit liability | 148 | 146 |
| Interest and dividend income | (43) | (52) |
| Decrease (increase) in trade receivables | (632) | (675) |
| Decrease (increase) in inventories | (1,563) | (1,899) |
| Increase (decrease) in trade payables | 1,461 | 635 |
| Increase (decrease) in advances received | 182 | 19 |
| Other | 1,394 | 1,937 |
| Subtotal | 13,266 | 13,585 |
| Interest and dividends received | 1 | 4 |
| Income taxes paid | (4,257) | (3,041) |
| Income taxes refund | 832 | 863 |
| Net cash provided by operating activities | 9,843 | 11,411 |
| Cash flows from investing activities | | |
| Purchase of property, plant and equipment | (6,416) | (4,614) |
| Purchase of intangible assets | (13) | (50) |
| Payments into time deposits | (400) | (400) |
| Proceeds from withdrawal of time deposits | 400 | 400 |
| Long-term loan advances | (222) | (464) |
| Proceeds from collection of long-term loans receivable | 516 | 527 |
| Payments of leasehold and guarantee deposits | (9) | (29) |
| Proceeds from refund of leasehold and guarantee deposits | 71 | 68 |
| Purchase of long-term prepaid expenses | (59) | (161) |
| Payments for store openings in progress | (5,442) | (3,235) |
| Payments into deposit money | (109) | (9) |
| Other | 38 | 0 |
| Net cash used in investing activities | (11,646) | (7,969) |
| Cash flows from financing activities | | |
| Dividends paid | (1,706) | (2,376) |
| Proceeds from disposal of treasury shares | — | 1,198 |
| Other | 22 | (15) |
| Net cash used in financing activities | (1,684) | (1,193) |
| Net increase (decrease) in cash and cash equivalents | (3,487) | 2,248 |
| Cash and cash equivalents at beginning of period | 37,126 | 37,812 |
| Cash and cash equivalents at end of period | 33,638 | 40,061 |

(4) Notes to Consolidated Financial Statements

Going concern assumption

Not applicable

Notes in case of significant changes in shareholders' equity

Following the disposal of treasury shares through the exercise of 1st and 2nd series share options issued on November 22, 2023, the Group's capital surplus in the first half of the fiscal year ending May 31, 2025 increased by 763 million yen and its treasury shares decreased by 438 million yen. As a result, the capital surplus as of November 30, 2024, stood at 3,709 million yen while treasury shares showed a negative figure of 2,705 million yen.

Application of specific accounting treatment in the preparation of consolidated financial statements

We make a reasonable estimate of the effective tax rate to be imposed on profit before income taxes in the fiscal year ending May 31, 2025, including the first six months, after applying tax effect accounting and perform the calculation by multiplying profit before income taxes by the estimated effective tax rate.

Changes to accounting policies

Application of accounting standard for current income taxes, etc.

The Accounting Standard for Current Income Taxes, etc. (Accounting Standard No. 27, issued on October 28, 2022) has been applied from the beginning of the first half of the fiscal year ending May 31, 2025.

There is no impact on the consolidated financial statements as a result of this application.

Changes in accounting estimates

Not applicable

Segment information

First six months of the fiscal year ended May 31, 2024 (From June 1, 2023 to November 30, 2023)

Since the Group has a high proportion of drug store business which is considered to be of little importance as disclosed information, segment information has been omitted.

First six months of the fiscal year ending May 31, 2025 (From June 1, 2024 to November 30, 2024)

Since the Group has a high proportion of drug store business which is considered to be of little importance as disclosed information, segment information has been omitted.

3. Supplemental Information

(1) Production, Orders Received, and Sales

1) Sales results

(i) Sales results by product division

Sales results by product division during the first half of the fiscal year ending May 31, 2025 were as follows:

| Product division | 1H of FY2024 (From June 1, 2024 to November 30, 2024) | |
|---------------------------------------|---|----------------|
| | Amount (millions of yen) | YoY change (%) |
| Drug Stores | | |
| Medical and health products | 57,543 | 105.3 |
| OTC | 30,358 | 99.5 |
| Prescription drug stores | 27,184 | 112.5 |
| Cosmetics | 25,261 | 105.1 |
| Food products | 95,521 | 111.0 |
| Daily products | 33,676 | 108.8 |
| Other | 10,322 | 107.9 |
| Subtotal | 222,325 | 108.3 |
| Supermarkets | 1,248 | 123.4 |
| Nursing Care | | |
| Paid assisted living facilities | 371 | 108.5 |
| Adult day care services | 759 | 104.3 |
| Subtotal | 1,130 | 105.6 |
| Revenue from contracts with customers | 224,704 | 108.4 |
| Other revenue (Note) | 101 | 122.2 |
| Total | 224,806 | 108.4 |

(Note) Other revenue includes rent income based on the Accounting Standard for Lease Transactions (ASBJ Statement No. 13).

(ii) Sales results by region

Sales results by region during the first half of the fiscal year ending May 31, 2025 were as follows:

| | 1H of FY2023 (From June 1, 2023 to November 30, 2023) | | 1H of FY2024 (From June 1, 2024 to November 30, 2024) | |
|----------|---|-----------|---|-----------|
| | Amount (millions of yen) | Share (%) | Amount (millions of yen) | Share (%) |
| Kanagawa | 127,074 | 61.3 | 136,701 | 60.8 |
| Tokyo | 29,596 | 14.3 | 30,956 | 13.8 |
| Shizuoka | 22,880 | 11.0 | 24,218 | 10.8 |
| Chiba | 17,340 | 8.4 | 20,721 | 9.2 |
| Other | 10,558 | 5.1 | 12,208 | 5.4 |
| Total | 207,451 | 100.0 | 224,806 | 100.0 |

(2) Purchase results

Purchase results by product division during the first half of the fiscal year ending May 31, 2025 were as follows:

| Product division | 1H of FY2024 (From June 1, 2024 to November 30, 2024) | |
|--|---|----------------|
| | Amount (millions of yen) | YoY change (%) |
| Drug Stores | | |
| Medical and health products | 34,381 | 105.9 |
| OTC | 17,800 | 101.3 |
| Prescription drug stores | 16,580 | 111.3 |
| Cosmetics | 15,931 | 105.2 |
| Food products | 83,768 | 111.0 |
| Daily products | 23,984 | 106.8 |
| Other | 8,376 | 108.6 |
| Subtotal | 166,443 | 108.6 |
| Supermarkets | 968 | 127.7 |
| Nursing Care | | |
| Paid assisted living facilities | — | — |
| Adult day care services | — | — |
| Subtotal | — | — |
| Purchases for revenue from contracts with customers | 167,411 | 108.7 |
| Other revenue | — | — |
| Total | 167,411 | 108.7 |